How Bad Is This News for Moderna?
Moderna (NASDAQ: MRNA) has lost a lot of its luster from a stock performance point of view. The shares have slipped more than 30% since the start of the year. Until recently, that didn't accompany any particularly bad news. Moderna continued to advance candidates in the pipeline. And it continued to report billions of dollars in sales and profit thanks to its coronavirus vaccine.
Recently, though, Moderna said something that isn't exactly the best news for one of its programs. In fact, it may be rather negative. Now, the question is: How bad is this news? And should it prompt you to flee this biotech stock? Let's take a look at what happened -- and what it means for the stock.
Image source: Getty Images.
Source Fool.com
